Drug Trial Radar · NCT06736704
SNV4818 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Feb 20, 2025
Primary completion
Apr 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Pikavation Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.
Conditions
- Advanced Solid Tumors
Interventions
SNV4818Drug
SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
FulvestrantDrug
Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
PalbociclibDrug
Palbociclib tablets will be administered by mouth on days 1-21 of a 28 day cycle. The Palbociclib starting dose will be 125 mg once-daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs)Time frame: First 28 days of study treatment
- Treatment Emergent Adverse Events (TEAEs)Time frame: From first SNV4818 dose through approximately 30 days following the last SNV4818 dose
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Thomas Jefferson University-Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Scientia Clinical Research
Randwick, New South Wales, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada · Recruiting
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.